AP2015008664A0 - Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK) - Google Patents
Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK)Info
- Publication number
- AP2015008664A0 AP2015008664A0 AP2015008664A AP2015008664A AP2015008664A0 AP 2015008664 A0 AP2015008664 A0 AP 2015008664A0 AP 2015008664 A AP2015008664 A AP 2015008664A AP 2015008664 A AP2015008664 A AP 2015008664A AP 2015008664 A0 AP2015008664 A0 AP 2015008664A0
- Authority
- AP
- ARIPO
- Prior art keywords
- janus
- jak
- pyrrolo
- inhibitors
- pyrimidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767947P | 2013-02-22 | 2013-02-22 | |
| PCT/IB2014/058889 WO2014128591A1 (en) | 2013-02-22 | 2014-02-11 | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2015008664A0 true AP2015008664A0 (en) | 2015-08-31 |
Family
ID=50151346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2015008664A AP2015008664A0 (en) | 2013-02-22 | 2014-02-11 | Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK) |
Country Status (47)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE036240T2 (hu) | 2010-08-18 | 2018-06-28 | Samumed Llc | Diketonok és hidroxiketonok mint kateninszignálút-aktivátorok |
| EP2948134B1 (en) | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mtor inhibitors |
| DK2968249T3 (en) | 2013-02-22 | 2019-03-04 | Samumed Llc | GAMMA DIKETONS AS WNT / BETA-CATENIN SIGNAL ROAD ACTIVATORS |
| SG11201505816UA (en) | 2013-02-22 | 2015-09-29 | Pfizer | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) |
| ES2750655T3 (es) * | 2014-08-12 | 2020-03-26 | Pfizer | Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa |
| MX368248B (es) | 2014-08-20 | 2019-09-25 | Samumed Llc | Gamma-dicetonas para tratamiento y prevencion de piel envejecida y arrugas. |
| US10174056B2 (en) * | 2015-05-29 | 2019-01-08 | Wuxi Fortune Pharmaceutical Co., Ltd | Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| MX2018004605A (es) | 2015-10-16 | 2018-11-29 | Abbvie Inc | Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma. |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN106831779B (zh) * | 2015-11-28 | 2019-07-19 | 南昌弘益药业有限公司 | 一类jak激酶抑制剂的新化合物 |
| WO2017143014A1 (en) * | 2016-02-16 | 2017-08-24 | Brian Kim | Jak inhibitors and uses thereof |
| AU2018205253B2 (en) | 2017-01-06 | 2022-01-13 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
| CN108794480A (zh) * | 2017-04-28 | 2018-11-13 | 天津药物研究院有限公司 | 吡咯并嘧啶类化合物、其制备方法和用途 |
| UA128288C2 (uk) | 2018-03-08 | 2024-05-29 | Інсайт Корпорейшн | СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
| AU2019299666B2 (en) | 2018-07-06 | 2024-07-11 | Pfizer Inc. | Manufacturing process and intermediates for a pyrrolo(2,3- d)pyrimidine compound and use thereof |
| CA3118488A1 (en) * | 2018-11-05 | 2020-05-14 | Avista Pharma Solutions, Inc. | Chemical compounds |
| PT3915989T (pt) * | 2019-01-30 | 2023-10-02 | Felicamed Biotechnology Co Ltd | Inibidor de jak e método de preparação do mesmo |
| EP3924355A1 (en) | 2019-02-15 | 2021-12-22 | Pfizer Inc. | Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof |
| US20220185816A1 (en) | 2019-03-14 | 2022-06-16 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine |
| WO2020261041A1 (en) * | 2019-06-27 | 2020-12-30 | Glenmark Life Sciences Limited | Process for preparation of abrocitinib |
| EP4028007A1 (en) | 2019-09-11 | 2022-07-20 | Pfizer Inc. | Treatment of hidradenitis with jak inhibitors |
| MX2022012135A (es) | 2020-04-04 | 2023-01-18 | Pfizer | Métodos para tratar la enfermedad de coronavirus de 2019. |
| CN113637018A (zh) | 2020-04-27 | 2021-11-12 | 苏州晶云药物科技股份有限公司 | 磺酰胺类化合物的晶型及其制备方法 |
| BR112022021525A2 (pt) * | 2020-05-28 | 2022-12-13 | Pfizer | Derivados de pirrolo [2,3-d] pirimidina |
| JP2023544495A (ja) * | 2020-09-11 | 2023-10-24 | ガルデルマ ホールディング エスエー | 新規ｊａｋ阻害剤化合物、その合成方法、及びその使用 |
| IL304874A (en) | 2021-02-02 | 2023-10-01 | Pfizer | A protocol for the treatment of chronic hand eczema |
| WO2023014049A1 (ko) * | 2021-08-02 | 2023-02-09 | 한국화학연구원 | 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물 |
| CN118255769A (zh) * | 2022-12-28 | 2024-06-28 | 格格巫（珠海）生物科技有限公司 | 一种立体异构体的制备方法及中间体 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
| KR19990067704A (ko) | 1992-12-17 | 1999-08-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물 |
| JPH06329674A (ja) | 1993-05-20 | 1994-11-29 | Teijin Ltd | ４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン |
| JPH06329675A (ja) | 1993-05-20 | 1994-11-29 | Teijin Ltd | ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体 |
| JPH08134068A (ja) | 1994-11-02 | 1996-05-28 | Teijin Ltd | ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体 |
| US6051578A (en) | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
| US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| JP4666762B2 (ja) | 1998-06-19 | 2011-04-06 | ファイザー・プロダクツ・インク | ピロロ［２．３−ｄ］ピリミジン化合物 |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| US6284766B1 (en) | 1999-04-30 | 2001-09-04 | Neurogen Corporation | 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| NZ518884A (en) | 1999-12-10 | 2004-02-27 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
| EP1244668B1 (en) | 2000-01-07 | 2006-04-05 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
| UA74370C2 (uk) | 2000-06-26 | 2005-12-15 | Пфайзер Продактс Інк. | Піроло(2,3-d)піримідинові сполуки як імуносупресори |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| AU2002360436A1 (en) | 2001-11-30 | 2003-06-17 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| WO2004032834A2 (en) | 2002-10-04 | 2004-04-22 | Merck & Co., Inc. | Thrombin inhibitors |
| KR100678800B1 (ko) | 2002-11-21 | 2007-02-05 | 화이자 프로덕츠 인코포레이티드 | 3-아미노-피페리딘 유도체 및 그의 제조 방법 |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| SG170783A1 (en) * | 2005-07-29 | 2011-05-30 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
| JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| EP2007373A4 (en) | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | INHIBITION OF ALPHA SYNUCLEINE TOXICITY |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| BRPI0820342A2 (pt) | 2007-11-07 | 2015-05-26 | Foldrx Pharmaceuticals Inc | Modulação de tráfego de proteína |
| AU2008326184A1 (en) | 2007-11-08 | 2009-05-14 | Pfizer Inc. | Cyclobutyl carboxylic acid derivatives |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| AU2009283844B2 (en) | 2008-08-20 | 2013-09-05 | Zoetis Services Llc | Pyrrolo[2,3-d]pyrimidine compounds |
| PE20110793A1 (es) | 2008-09-18 | 2011-10-31 | Pfizer Ltd | Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona |
| PE20121077A1 (es) * | 2009-10-15 | 2012-08-10 | Pfizer | Compuestos de pirrolo[2,3-d]pirimidina |
| RU2711869C3 (ru) | 2009-12-01 | 2022-02-02 | Эббви Инк. | Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk |
| WO2011075334A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| TW201129565A (en) | 2010-01-12 | 2011-09-01 | Hoffmann La Roche | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| CN104224737A (zh) | 2010-02-24 | 2014-12-24 | 硕腾有限责任公司 | 兽医组合物 |
| CN103097340B (zh) | 2010-07-16 | 2018-03-16 | 安吉奥斯医药品有限公司 | 治疗活性组合物及其使用方法 |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| MX2013006251A (es) | 2010-12-03 | 2013-10-01 | Epizyme Inc | Compuestos de purina y 7 - deazapurina substituidos como moduladores de enzimas epigeneticas. |
| US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
| MX2013014427A (es) | 2011-06-07 | 2014-01-23 | Dainippon Sumitomo Pharma Co | Derivado de indazol y pirrolopiridina y uso farmaceutico del mismo. |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| US9527851B2 (en) * | 2011-12-21 | 2016-12-27 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof |
| US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| MX360857B (es) | 2012-07-20 | 2018-11-20 | Zoetis Llc | Régimen de dosificación para inhibidores de janus quinasa (jak). |
| JP2014133739A (ja) | 2012-12-12 | 2014-07-24 | Dainippon Sumitomo Pharma Co Ltd | インダゾール誘導体またはピロロピリジン誘導体からなる医薬 |
| SG11201505816UA (en) * | 2013-02-22 | 2015-09-29 | Pfizer | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak) |
| ES2750655T3 (es) | 2014-08-12 | 2020-03-26 | Pfizer | Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa |
-
2014
- 2014-02-11 SG SG11201505816UA patent/SG11201505816UA/en unknown
- 2014-02-11 CA CA2900703A patent/CA2900703C/en active Active
- 2014-02-11 RS RS20190097A patent/RS58245B1/sr unknown
- 2014-02-11 HU HUE14705887A patent/HUE037192T2/hu unknown
- 2014-02-11 MA MA38347A patent/MA38347A1/fr unknown
- 2014-02-11 LT LTEP14705887.9T patent/LT2958921T/lt unknown
- 2014-02-11 MD MDA20150073A patent/MD4735C1/ro active IP Right Grant
- 2014-02-11 EA EA201591255A patent/EA027879B1/ru unknown
- 2014-02-11 RS RS20171095A patent/RS56503B1/sr unknown
- 2014-02-11 AP AP2015008664A patent/AP2015008664A0/xx unknown
- 2014-02-11 JP JP2015558572A patent/JP6145179B2/ja active Active
- 2014-02-11 ES ES17191163T patent/ES2713052T3/es active Active
- 2014-02-11 PT PT17191163T patent/PT3290421T/pt unknown
- 2014-02-11 HU HUE17191163A patent/HUE041778T2/hu unknown
- 2014-02-11 NZ NZ710411A patent/NZ710411A/en unknown
- 2014-02-11 SI SI201431068T patent/SI3290421T1/sl unknown
- 2014-02-11 CN CN201710440379.1A patent/CN107089985B/zh active Active
- 2014-02-11 ME MEP-2019-6A patent/ME03301B/me unknown
- 2014-02-11 CN CN201480009783.8A patent/CN105008362B/zh active Active
- 2014-02-11 TR TR2019/02525T patent/TR201902525T4/tr unknown
- 2014-02-11 DK DK14705887.9T patent/DK2958921T3/da active
- 2014-02-11 ME MEP-2017-246A patent/ME02904B/me unknown
- 2014-02-11 SI SI201430459T patent/SI2958921T1/sl unknown
- 2014-02-11 GE GEAP201413916A patent/GEP201606600B/en unknown
- 2014-02-11 ES ES14705887.9T patent/ES2647525T3/es active Active
- 2014-02-11 PT PT147058879T patent/PT2958921T/pt unknown
- 2014-02-11 PL PL17191163T patent/PL3290421T3/pl unknown
- 2014-02-11 MY MYPI2015702431A patent/MY177476A/en unknown
- 2014-02-11 EP EP17191163.9A patent/EP3290421B1/en active Active
- 2014-02-11 LT LTEP17191163.9T patent/LT3290421T/lt unknown
- 2014-02-11 PE PE2015001766A patent/PE20151764A1/es active IP Right Grant
- 2014-02-11 PL PL14705887T patent/PL2958921T3/pl unknown
- 2014-02-11 WO PCT/IB2014/058889 patent/WO2014128591A1/en active Application Filing
- 2014-02-11 BR BR112015019634-9A patent/BR112015019634B1/pt active IP Right Grant
- 2014-02-11 DK DK17191163.9T patent/DK3290421T3/en active
- 2014-02-11 CU CUP2015000078A patent/CU24275B1/xx unknown
- 2014-02-11 AU AU2014220357A patent/AU2014220357B2/en active Active
- 2014-02-11 MX MX2015010928A patent/MX2015010928A/es active IP Right Grant
- 2014-02-11 EP EP14705887.9A patent/EP2958921B1/en active Active
- 2014-02-11 KR KR1020157022489A patent/KR101787858B1/ko active IP Right Grant
- 2014-02-19 TW TW103105469A patent/TWI507408B/zh active
- 2014-02-19 US US14/183,946 patent/US9035074B2/en active Active
- 2014-02-20 UY UY0001035337A patent/UY35337A/es not_active Application Discontinuation
- 2014-02-21 AR ARP140100561A patent/AR094857A1/es active IP Right Grant
- 2014-09-24 NO NO14789648A patent/NO3052752T3/no unknown
- 2014-11-02 UA UAA201507511A patent/UA111804C2/uk unknown
-
2015
- 2015-04-21 US US14/691,606 patent/US9545405B2/en active Active
- 2015-05-18 US US14/715,046 patent/US9549929B2/en active Active
- 2015-07-23 IL IL240132A patent/IL240132B/en active IP Right Grant
- 2015-07-29 ZA ZA2015/05454A patent/ZA201505454B/en unknown
- 2015-07-30 CR CR20150395A patent/CR20150395A/es unknown
- 2015-08-12 PH PH12015501779A patent/PH12015501779B1/en unknown
- 2015-08-17 CL CL2015002303A patent/CL2015002303A1/es unknown
- 2015-08-18 TN TN2015000355A patent/TN2015000355A1/fr unknown
- 2015-08-21 DO DO2015000206A patent/DOP2015000206A/es unknown
-
2016
- 2016-02-18 HK HK16101741.2A patent/HK1213881A1/zh unknown
-
2017
- 2017-05-11 JP JP2017094676A patent/JP2017165762A/ja active Pending
- 2017-10-19 HR HRP20171599TT patent/HRP20171599T2/hr unknown
- 2017-10-26 CY CY20171101116T patent/CY1119502T1/el unknown
-
2019
- 2019-01-23 HR HRP20190152TT patent/HRP20190152T1/hr unknown
- 2019-01-30 CY CY20191100127T patent/CY1121468T1/el unknown
-
2021
- 2021-12-22 NL NL301155C patent/NL301155I2/nl unknown
-
2022
- 2022-01-12 CY CY2022003C patent/CY2022003I2/el unknown
- 2022-01-17 HU HUS2200003C patent/HUS2200003I1/hu unknown
- 2022-01-26 LT LTPA2022502C patent/LTPA2022502I1/lt unknown
- 2022-02-01 NO NO2022004C patent/NO2022004I1/no unknown
- 2022-02-10 FR FR22C1006C patent/FR22C1006I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200003I1 (hu) | Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai | |
| HK1222659A1 (zh) | 吡咯並 嘧啶衍生物，它們的製備方法和它們作爲激酶抑制劑的用途 | |
| HRP20171724T1 (hr) | Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze | |
| HK1255467A1 (zh) | 作為雙重dyrk1/clk1抑制劑的新的吡咯並[2，3-d]嘧啶衍生物 | |
| SG11201600062RA (en) | Pyrimidine derivatives as kinase inhibitors | |
| IL228590A0 (en) | History of pyrrolo[3,2-d] pyrimidine as inhibitors of tropomyosin-linked kinases | |
| EP2999702A4 (en) | Substituted pyrazolopyrimidines as kinases inhibitors | |
| LT2948443T (lt) | Nauji pirimidino dariniai kaip fosfodiesterazės 10 inhibitoriai (pde-10) |